Roquefort Therapeutics plc Stock price

Equities

ROQ

GB00BMDQ2T15

Investment Management & Fund Operators

Market Closed - London S.E. 12:35:25 2024-03-28 pm EDT 5-day change 1st Jan Change
7 GBX -3.45% Intraday chart for Roquefort Therapeutics plc -3.45% -3.45%
Sales 2021 637 804.06 Sales 2022 - Capitalization 8.56M 10.8M
Net income 2021 - 0 Net income 2022 -1M -1.26M EV / Sales 2021 10,439 x
Net cash position 2021 900K 1.14M Net cash position 2022 2.32M 2.93M EV / Sales 2022 -
P/E ratio 2021
-3.77 x
P/E ratio 2022
-4.24 x
Employees 9
Yield 2021 *
-
Yield 2022
-
Free-Float 48.51%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.45%
1 week-3.45%
Current month-17.65%
1 month-20.00%
3 months-6.67%
6 months-8.20%
Current year-3.45%
More quotes
1 week
6.80
Extreme 6.8
7.42
1 month
6.79
Extreme 6.789
9.00
Current year
5.84
Extreme 5.844
9.50
1 year
5.75
Extreme 5.75
9.50
3 years
5.75
Extreme 5.75
13.63
5 years
5.75
Extreme 5.75
13.63
10 years
5.75
Extreme 5.75
13.63
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 22-09-15
Chairman 51 20-08-16
Chief Tech/Sci/R&D Officer - 22-09-15
Members of the board TitleAgeSince
Director/Board Member 63 22-04-04
Director/Board Member 57 22-09-15
Chairman 51 20-08-16
More insiders
Date Price Change Volume
24-03-28 7 -3.45% 277,459
24-03-27 7.25 0.00% 168,143
24-03-26 7.25 0.00% 0
24-03-25 7.25 0.00% 33,551
24-03-22 7.25 0.00% 0

Delayed Quote London S.E., March 28, 2024 at 12:35 pm EDT

More quotes
Roquefort Therapeutics PLC is a biotechnology company. The Company is focused on developing pre-clinical medicines focused on treating hard-to-treat cancers. The Company’s portfolio consists of five fully funded, patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines includes Midkine antibodies with in vivo efficacy and toxicology studies; Midkine oligonucleotide therapeutics with anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with in vivo efficacy, and MK cell therapy with direct and NK-mediated anti-cancer action. The Company operates through its subsidiaries Lyramid Pty Ltd (Lyramid) and Oncogeni Ltd. Lyramid is engaged in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression). Oncogeni Ltd has developed two families of cell and RNA oncology medicines.
More about the company
  1. Stock
  2. Equities
  3. Stock Roquefort Therapeutics plc - London S.E.